A detailed history of Arrow Mark Colorado Holdings LLC transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Arrow Mark Colorado Holdings LLC holds 882,731 shares of AGIO stock, worth $37.7 Million. This represents 0.56% of its overall portfolio holdings.

Number of Shares
882,731
Previous 1,019,357 13.4%
Holding current value
$37.7 Million
Previous $44 Million 10.77%
% of portfolio
0.56%
Previous 0.58%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$41.19 - $49.72 $5.63 Million - $6.79 Million
-136,626 Reduced 13.4%
882,731 $39.2 Million
Q2 2024

Aug 14, 2024

SELL
$27.55 - $48.83 $13.8 Million - $24.4 Million
-499,806 Reduced 32.9%
1,019,357 $44 Million
Q1 2024

May 15, 2024

SELL
$21.32 - $34.81 $740,209 - $1.21 Million
-34,719 Reduced 2.23%
1,519,163 $44.4 Million
Q4 2023

Feb 14, 2024

SELL
$19.97 - $24.53 $386,858 - $475,195
-19,372 Reduced 1.23%
1,553,882 $34.6 Million
Q2 2023

Aug 14, 2023

BUY
$21.38 - $29.19 $332,437 - $453,875
15,549 Added 1.0%
1,573,254 $44.6 Million
Q1 2023

May 15, 2023

BUY
$21.74 - $30.93 $2.54 Million - $3.61 Million
116,719 Added 8.1%
1,557,705 $35.8 Million
Q4 2022

Feb 14, 2023

BUY
$24.81 - $31.52 $1.5 Million - $1.91 Million
60,597 Added 4.39%
1,440,986 $40.5 Million
Q3 2022

Nov 14, 2022

BUY
$19.51 - $34.14 $50,901 - $89,071
2,609 Added 0.19%
1,380,389 $39 Million
Q2 2022

Aug 15, 2022

BUY
$17.06 - $31.42 $1.4 Million - $2.57 Million
81,832 Added 6.31%
1,377,780 $30.5 Million
Q1 2022

May 16, 2022

SELL
$26.68 - $34.81 $432,642 - $564,478
-16,216 Reduced 1.24%
1,295,948 $37.7 Million
Q4 2021

Feb 14, 2022

BUY
$29.58 - $49.78 $6.86 Million - $11.5 Million
231,855 Added 21.46%
1,312,164 $43.1 Million
Q3 2021

Nov 15, 2021

BUY
$41.92 - $58.18 $1.97 Million - $2.73 Million
46,878 Added 4.54%
1,080,309 $49.9 Million
Q2 2021

Aug 16, 2021

SELL
$52.06 - $61.27 $4.48 Million - $5.28 Million
-86,135 Reduced 7.69%
1,033,431 $57 Million
Q1 2021

May 17, 2021

SELL
$44.23 - $57.5 $2.14 Million - $2.78 Million
-48,369 Reduced 4.14%
1,119,566 $57.8 Million
Q4 2020

Feb 16, 2021

BUY
$33.21 - $46.54 $2.86 Million - $4.01 Million
86,111 Added 7.96%
1,167,935 $50.6 Million
Q3 2020

Nov 16, 2020

BUY
$33.87 - $55.93 $32,853 - $54,252
970 Added 0.09%
1,081,824 $37.9 Million
Q2 2020

Aug 14, 2020

SELL
$34.45 - $53.48 $943,482 - $1.46 Million
-27,387 Reduced 2.47%
1,080,854 $57.8 Million
Q1 2020

May 15, 2020

SELL
$31.52 - $53.81 $5,043 - $8,609
-160 Reduced 0.01%
1,108,241 $39.3 Million
Q4 2019

Feb 14, 2020

BUY
$30.08 - $50.59 $2.09 Million - $3.51 Million
69,326 Added 6.67%
1,108,401 $52.9 Million
Q3 2019

Nov 14, 2019

BUY
$32.4 - $49.58 $7.04 Million - $10.8 Million
217,359 Added 26.45%
1,039,075 $33.7 Million
Q2 2019

Aug 14, 2019

BUY
$46.17 - $68.1 $3.87 Million - $5.71 Million
83,820 Added 11.36%
821,716 $41 Million
Q1 2019

May 15, 2019

BUY
$45.92 - $67.67 $2.58 Million - $3.8 Million
56,093 Added 8.23%
737,896 $49.8 Million
Q4 2018

Feb 14, 2019

BUY
$42.73 - $76.53 $1.42 Million - $2.54 Million
33,147 Added 5.11%
681,803 $31.4 Million
Q3 2018

Nov 14, 2018

BUY
$71.67 - $91.95 $6.77 Million - $8.68 Million
94,392 Added 17.03%
648,656 $50 Million
Q2 2018

Aug 14, 2018

SELL
$73.22 - $99.55 $1.29 Million - $1.76 Million
-17,650 Reduced 3.09%
554,264 $46.7 Million
Q1 2018

May 15, 2018

BUY
$59.83 - $86.53 $25.9 Million - $37.5 Million
433,546 Added 313.33%
571,914 $46.8 Million
Q3 2017

Nov 14, 2017

BUY
$54.89 - $67.12 $7.6 Million - $9.29 Million
138,368
138,368 $9.24 Million

Others Institutions Holding AGIO

About AGIOS PHARMACEUTICALS, INC.


  • Ticker AGIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,818,000
  • Market Cap $2.34B
  • Description
  • Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...
More about AGIO
Track This Portfolio

Track Arrow Mark Colorado Holdings LLC Portfolio

Follow Arrow Mark Colorado Holdings LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrow Mark Colorado Holdings LLC, based on Form 13F filings with the SEC.

News

Stay updated on Arrow Mark Colorado Holdings LLC with notifications on news.